SIGNABLOK, INC.

SIGNABLOK, INC. is a biotech company in WORCESTER, United States, founded in 2015. It has raised $9.4M across 13 rounds, most recently a $1.4M Grant in December 2025.

Homepage - SignaBlok

Employees
1–10
Founded
2015
Total Funding
$9.4M
Last Round
$1.4M GrantDec 2025
Rounds
13

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 13 funding rounds and 2 investors for this company. The full record is or through the API.

About

SignaBlok develops peptide therapeutics and multifunctional nanosystems for targeted delivery of therapeutics, other drugs, and imaging agents to inflammation sites. Its pipeline uses proprietary technologies to image macrophages and shape their biology in inflammation-associated diseases and disorders. Its research focuses on cancer, atherosclerosis, inflammatory diseases, and immune diseases.

Summary

It lists 1–10 employees. It has raised $9.4M in total across 13 rounds, most recently a $1.4M Grant round in Dec 2025. Investors include Department of Health and Human Services and Checkmate Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
GrantDec 2025
$1.4M

Sign up to see all 13 events

Funding: Grant. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

SIGNABLOK, INC. on Indexed.vc
<a href="https://indexed.vc/companies/signablok-inc"><img src="https://indexed.vc/api/badge/company/signablok-inc" alt="SIGNABLOK, INC. on Indexed.vc" width="260" height="76" /></a>